Welcome to our dedicated page for ESSA Pharma news (Ticker: EPIX), a resource for investors and traders seeking the latest updates and insights on ESSA Pharma stock.
ESSA Pharma Inc. (NASDAQ: EPIX) is a clinical-stage pharmaceutical company dedicated to advancing novel therapeutics for cancer patients, specifically those battling castration-resistant prostate cancer (CRPC). Founded on cutting-edge research, ESSA Pharma is pioneering the development of small molecule drugs that selectively target the amino-terminal domain of the androgen receptor. This innovative approach aims to overcome known AR-dependent resistance mechanisms in CRPC, potentially offering improved progression-free and overall survival for patients.
ESSA Pharma's flagship candidate, Masofaniten (formerly EPI-7386), is a first-in-class N-terminal domain androgen receptor (AR) inhibitor. Additionally, the company has demonstrated promising results in Phase 1/2 clinical trials that combine Masofaniten with Enzalutamide, another AR inhibitor. These trials have shown deep, durable reductions in prostate-specific antigen (PSA) levels, which are crucial markers in prostate cancer treatment.
Recent data presented at the European Society of Medical Oncology (ESMO) 2023 Congress and the Prostate Cancer Foundation Scientific Retreat reveal that the combination therapy of Masofaniten and Enzalutamide is well-tolerated and effective in reducing PSA levels in patients with metastatic CRPC. The randomized Phase 2 dose expansion study is currently enrolling, with the goal of further elucidating the clinical benefits of this combination therapy.
In recent developments, ESSA Pharma has entered into an ATM Sales Agreement with Jefferies LLC to raise up to US$50 million in capital, ensuring a strong financial runway for ongoing and future projects. The company also reported encouraging financial results for the fiscal year ended September 30, 2023, and the fiscal first quarter of 2024, reflecting a robust cash position expected to fund operations through 2025.
ESSA Pharma's strategy includes exploring additional combinations of Masofaniten with other standard-of-care antiandrogens. The U.S. Food and Drug Administration has granted Fast Track designation to Masofaniten for the treatment of adult male patients with mCRPC resistant to standard-of-care treatments, underscoring the potential importance of this therapy.
For more information, visit the company’s website at www.essapharma.com, or follow them on Twitter and LinkedIn.
ESSA Pharma Inc. (NASDAQ: EPIX), a clinical-stage pharmaceutical company, announced its participation at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023, at 2:00 p.m. Eastern Time in Toronto, Ontario. Key executives, including President and CEO David R. Parkinson, COO Peter Virsik, and CFO David S. Wood, will engage in one-on-one meetings with investors.
The conference connects U.S. and Canadian investors with updates on the Canadian healthcare sector and features both presentations and private meetings with prominent companies. A live webcast of ESSA's presentation will be available on the company’s website, with an archived version accessible for 90 days thereafter.
ESSA Pharma Inc. (NASDAQ: EPIX) announced a clinical trial support agreement with Janssen Research & Development to evaluate EPI-7386, a first-in-class N-terminal domain androgen receptor inhibitor, in combination with apalutamide and abiraterone acetate plus prednisone for prostate cancer treatment. The Phase 1 trial will assess safety, pharmacokinetics, and anti-tumor activity in metastatic castration-resistant prostate cancer (mCRPC) and high-risk metastatic castration-sensitive prostate cancer (mCSPC) patients. ESSA retains all rights to EPI-7386, which has received Fast Track designation from the FDA. Preliminary data indicate a favorable safety profile and early signs of anti-tumor activity.
Summit Therapeutics (SMMT) reported its financial results for the fourth quarter and year ending December 31, 2022. The company is progressing with its Collaboration and License Agreement with Akeso, acquiring rights to ivonescimab, a bispecific antibody for cancer treatment, for an upfront payment of $500 million. Key financials include a net loss of $78.8 million for the year, a significant decrease from $88.6 million in 2021. Summit raised $500 million in a Rights Offering to fund ongoing operations, with sufficient capital expected to cover expenses into late 2024. An earnings call is scheduled for March 9, 2023.
ESSA Pharma Inc. (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on prostate cancer therapies, announced its presentation at the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023, at 11:20 a.m. Eastern Time. The event will feature David R. Parkinson, President and CEO, along with COO Peter Virsik and CFO David S. Wood, who will also participate in one-on-one meetings. Investors can access a live webcast through ESSA's website, with an archived version available for 90 days post-event. ESSA aims to develop novel therapies to improve prostate cancer treatment outcomes.
On February 13, 2023, ESSA Pharma Inc. (NASDAQ: EPIX) announced that further analyses from two Phase 1 studies of EPI-7386 will be presented at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium from February 16-19 in San Francisco. EPI-7386 is a novel androgen receptor inhibitor showing promising initial anti-tumor activity in metastatic castration-resistant prostate cancer (mCRPC). Early data indicates that the combination with enzalutamide has led to sustained declines in prostate-specific antigen (PSA) levels in patients. ESSA is preparing to enroll 120 patients in a Phase 2 study across the U.S., Canada, and Australia.
FAQ
What is the current stock price of ESSA Pharma (EPIX)?
What is the market cap of ESSA Pharma (EPIX)?
What is ESSA Pharma Inc. focused on?
What is Masofaniten?
What recent achievements has ESSA Pharma reported?
What is the significance of the Phase 1/2 clinical trials?
What are the future plans for ESSA Pharma?
What financial position is ESSA Pharma in?
What designations has Masofaniten received from regulatory authorities?
Where can I find more information about ESSA Pharma?
How does Masofaniten work?
What partnerships does ESSA Pharma have?
